Key facts
- This page summarizes Robert E. Hoffman's Form 3/A filing for FibroBiologics, Inc. (FBLG).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 13 Aug 2024, 16:01.
Robert E. Hoffman - 24 Jan 2024 Form 3/A Insider Report for FibroBiologics, Inc. (FBLG)
- Reporting relationship
- Director
- Issuer ticker
- FBLG
- Reported as of
- 24 Jan 2024
- Net transaction value
- $0
- SEC form
- 3/A
- Accepted by SEC
- 13 Aug 2024, 16:01:17 UTC
- Original report date
- 07 Feb 2024
- Prior SEC filing
- 01 Sep 2023
- Next SEC filing
- 27 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Andersen, by Power of Attorney
Source evidence
Original filing metadata and source links for verification.
6 source fields
Reporting owner
1 detail
Key filing fact
Robert E. Hoffman filed Form 3/A for FibroBiologics, Inc. (FBLG) on 13 Aug 2024.
Change
- Previous filing in this sequence was filed on 01 Sep 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3/A disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
FBLG
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 24 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 185,300
- Exercise price
- $2.28
- Footnotes
- F1
FBLG
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 24 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,000
- Exercise price
- $3.28
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
1/4 of the options vested on January 1, 2024, with the remainder vesting monthly over 36 months.
Footnote F2
All options vested on September 26, 2023, the one-year anniversary of the date of grant.
SEC remarks
This amendment is filed to include stock options in Table II that were inadvertently omitted in the original filing.